期刊
CLINICAL AND MOLECULAR HEPATOLOGY
卷 29, 期 -, 页码 S207-S219出版社
KOREAN ASSOC STUDY LIVER
DOI: 10.3350/cmh.2022.0247
关键词
Liver neoplasm; Non-alcoholic fatty liver disease; Early detection of cancer; Population surveillance; Hepatocellular carcinoma
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of hepatocellular carcinoma (HCC), and HCC surveillance is recommended for patients with cirrhosis from any cause and may be beneficial for high-risk subgroups with non-cirrhotic NAFLD. NAFLD-related HCC patients are more likely to have advanced stage cancer and poor outcomes due to suboptimal effectiveness of surveillance programs. This review summarizes current HCC surveillance guidelines, discusses challenges specific to NAFLD, and examines the effectiveness of current surveillance tools while suggesting future approaches to improve adherence.
Non-alcoholic fatty liver disease (NAFLD) may progress to cirrhotic or non-cirrhotic hepatocellular carcinoma (HCC), and is currently recognized as the fastest growing cause of HCC worldwide. Accordingly, professional society guidelines recommend HCC surveillance in patients with cirrhosis from any etiology, and some may consider it beneficial in subgroups with non-cirrhotic NAFLD at higher risk for HCC. Notably, patients with NAFLD-related HCC are more likely to have HCC diagnosed at more advanced stages and have poorer outcomes when compared to other etiologies, and suboptimal effectiveness of HCC surveillance programs is a major culprit. In this review, we summarize the current guidelines for HCC surveillance and discuss its benefits versus potential harms for NAFLD patients. We also address the unique challenges of HCC surveillance in NAFLD, including higher proportion of NAFLD-related HCC without cirrhosis, poor recognition of at-risk patients, lack of consensus regarding the value of surveillance in non- cirrhotic NAFLD, subpar effectiveness of surveillance tools related to NAFLD phenotype, and preponderant surveillance underuse among NAFLD patients. Finally, we examine the effectiveness of currently used surveillance tools (i.e., ultrasound and alpha fetoprotein) and outline future perspectives including emerging risk stratification tools, imaging surveillance strategies (e.g., abbreviated magnetic resonance imaging protocols), blood-based biomarkers (e.g., GALAD and circulating tumor DNA panels), and interventions to improve surveillance adherence.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据